CClinicalTrials.gg
WithdrawnNCT03894306Updated Dec 10, 2021

Understanding How Medication is Stored in the Home

An observational study in Poisoning, sponsored by NYU Langone Health. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-10.

Sponsored by NYU Langone Health · Observational

Why this study was withdrawn
Unable to enroll any patients due to COVID
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
0
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this study is to increase safe medication storage practices in homes with young children in order to prevent unintentional childhood poisonings.

As a step toward meeting this goal, this study aims to determine if an intervention to promote safe storage to patients who have young children in their home, including provision of a lock box or lock bag along with brief counseling versus brief counseling alone, results in 1) increased locked storage (and overall safe medication storage practices) of high-risk prescription medications in the home; 2) increased safe medication storage practices of other medications in the home; and 3) improved safe medication storage related knowledge and attitudes.

02

Conditions studied

  • Poisoning

Browse trials for

03

In context

Poisoning

209 studies on the registry are indexed under Poisoning; 26 are open to participants now.

Browse Poisoning studies →

Lead sponsor

NYU Langone Health is the lead sponsor of 1,391 studies on the registry; 254 are open to participants now.

Of its 227 completed or terminated interventional studies of FDA-regulated products, 191 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients in the buprenorphine clinic, high A1c clinic, or palliative care clinics at NYC Health + Hospitals/Bellevue who are prescribed at least one high-risk medication and have a child less than six years old present in his/her home on average at least 8 hours per week.

Inclusion criteria

  • Patient in the buprenorphine clinic, high A1c clinic, or palliative care clinic at NYC Health + Hospitals/Bellevue
  • Patient prescribed at least one high-risk mediation. A high-risk medication defined as a prescription medication that may cause significant toxicity or death with the ingestion of only one pill or a single adult dose.
  • A child less than six years old is present in the patient's home on average at least 8 hours per week.

Exclusion criteria

Exclusion Criteria:

  • Inability to speak and read English or Spanish
  • No phone number for follow-up or unwilling to do follow-up by phone or in person
  • Prior enrollment
  • Patient was involved in pilot study
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
0 participants (actual)
Patient registry
No

Groups and cohorts

  • medication lock box + brief counseling

    Other: Medication lock box · Other: brief counseling

  • medication lock bag + brief counseling

    Other: medication lock bag · Other: brief counseling

  • brief counseling alone

    Other: brief counseling

Interventions

  • OtherMedication lock box

    given a lock box and instructed on how to use the device.

  • Othermedication lock bag

    given a lock bag and instructed on how to use the device.

  • Otherbrief counseling

    After completing the per-intervention survey, a research assistant or investigator will perform brief counseling, including educational handouts and information on safe medication storage

06

What researchers measure

Primary outcomes

  1. Percentage of patients with locked storage of all high-risk prescription medications at one month follow-up.

    Time frame: 1 Months

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03894306
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Mar 28, 2019
Start date
Jun 2021 (estimated)
Primary completion
Jun 2022 (estimated)
Completion
Jun 2022 (estimated)
Last update
Dec 10, 2021

Study contacts

Mark K Su, MD
principal investigator · NYU Langone Health - Toxicology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion